| For quite some time, there has been evidence to suggest that a drug used to treat type 2 diabetes, known as metformin, can also slow certain types of cancers. But, until now, researchers didn't know why metformin had this effect.
In a new study, a research team at Massachusetts General Hospital led by Alexander Soukas, MD, PhD, Assistant Professor of Medicine, Harvard Medical School, has revealed a biological discovery that could be a target for drugs that fight cancer and appears to be responsible for metformin's ability to slow the growth of human cancer cells.
When you renew your support of the MGH Fund today with a gift of $35, $50 or $100, you'll help ensure that lack of funding doesn't stand in the way of our researchers and their potentially life-saving work.
By shedding new light on metformin's health-promoting effects, our researchers have offered new ways to think about treating cancer.
Current clinical trials are testing the impact of metformin on cancers of the breast, prostate and pancreas; and several research groups at Mass General are working to identify its molecular targets.
But more research is needed to turn these types of discoveries into new therapies that transform people's lives, which can be made possible by supporting the MGH Fund.
Help us by making a critically needed gift of $35, $50 or $100 today to the MGH Fund to provide the vital funding required to push through when we're on the verge of a major medical breakthrough.
Peter L. Slavin, MD
President, Massachusetts General Hospital
P.S. Your renewed support of the MGH Fund is crucial today to help ensure our researchers have the resources they need to make life-saving discoveries.
| 
Posts
No comments:
Post a Comment